MA30690B1 - Triazolyle phenyle benzenesulfonamides - Google Patents

Triazolyle phenyle benzenesulfonamides

Info

Publication number
MA30690B1
MA30690B1 MA31566A MA31566A MA30690B1 MA 30690 B1 MA30690 B1 MA 30690B1 MA 31566 A MA31566 A MA 31566A MA 31566 A MA31566 A MA 31566A MA 30690 B1 MA30690 B1 MA 30690B1
Authority
MA
Morocco
Prior art keywords
ccr2
ccr9
compounds
antagonists
assays
Prior art date
Application number
MA31566A
Other languages
English (en)
Inventor
Trevor T Charvat
Cheng Hu
Anita Melikian
Aaron Novack
Andrew M K Pennell
Edward J Sullivan
Xuefei Tan
William D Thomas
Solomon Ungashe
Yibin Zeng
Sreenivas Punna
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA30690B1 publication Critical patent/MA30690B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS SUSCEPTIBLES D'AGIR COMME DE PUISSANTS ANTAGONISTES DU RÉCEPTEUR CCR2 OU CCR9. DES ESSAIS SUR DES ANIMAUX DÉMONTRENT L'UTILILTÉ DE CES COMPOSÉS POUR LE TRAITEMENT D'INFLAMMATIONS, UNE MALADIE CARACTÉRISTIQUE POUR CCR2 ET CCR9. CES COMPOSÉS SONT GÉNÉRALEMENT DES DÉRIVÉS D'ARYLSULFONAMIDE QUE L'ON UTILISE DANS DES COMPOSITIONS PHARMACEUTIQUES, DES PROCÉDÉS DE TRAITEMENT DE MALADIES MÉDIÉES PAR CCR2, CCR9, COMME TÉMOINS DANS DES DOSAGES POUR L'IDENTIFICATION D'ANTAGONISTES DE CCR2 ET POUR L'IDENTIFICATION D'ANTAGONISTES DE CCR9.
MA31566A 2006-07-14 2009-01-12 Triazolyle phenyle benzenesulfonamides MA30690B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83104206P 2006-07-14 2006-07-14
US94583907P 2007-06-22 2007-06-22

Publications (1)

Publication Number Publication Date
MA30690B1 true MA30690B1 (fr) 2009-09-01

Family

ID=38896161

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31566A MA30690B1 (fr) 2006-07-14 2009-01-12 Triazolyle phenyle benzenesulfonamides

Country Status (21)

Country Link
EP (1) EP2046762B1 (fr)
JP (1) JP5266219B2 (fr)
KR (1) KR101433392B1 (fr)
AT (1) ATE498615T1 (fr)
AU (1) AU2007275873B2 (fr)
BR (1) BRPI0714407A2 (fr)
CA (1) CA2657776C (fr)
CO (1) CO6180465A2 (fr)
DE (1) DE602007012552D1 (fr)
DK (1) DK2046762T3 (fr)
EA (1) EA015710B1 (fr)
IL (1) IL196409A (fr)
MA (1) MA30690B1 (fr)
MX (1) MX2009000395A (fr)
NO (1) NO341949B1 (fr)
NZ (1) NZ574759A (fr)
PL (1) PL2046762T3 (fr)
PT (1) PT2046762E (fr)
UA (1) UA98304C2 (fr)
WO (1) WO2008010934A2 (fr)
ZA (1) ZA200900281B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049515B1 (fr) 2006-07-14 2011-01-26 ChemoCentryx, Inc. Triazolyl pyridyl benzènesulfonamides en tant que modulateurs du ccr2 ou ccr9 pour le traitement l'athérosclérose
NZ579403A (en) * 2007-02-08 2012-03-30 Synta Pharmaceuticals Corp Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2010005922A1 (fr) * 2008-07-07 2010-01-14 Fasgen, Inc. Nouveaux composés, compositions pharmaceutiques les contenant, et leurs procédés d'utilisation et de préparation
WO2011082271A2 (fr) 2009-12-30 2011-07-07 Arqule, Inc. Composés triazolo-pyrimidine substitués
US8691184B2 (en) * 2011-01-25 2014-04-08 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
EP2734204A4 (fr) * 2011-07-22 2015-03-18 Chemocentryx Inc Formes polymorphes du sel de sodium de 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phényl]-benzène- sulfonamide
CN103842343B (zh) * 2011-07-22 2016-08-31 坎莫森特里克斯公司 4-叔丁基-n-[4-氯-2-(1-氧基-吡啶-4-羰基)-苯基]-苯磺酰胺的钠盐的晶形
RU2607514C2 (ru) * 2011-07-22 2017-01-10 Хемоцентрикс, Инк. Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида
CA2852160A1 (fr) 2011-10-28 2013-05-02 Galderma Research & Development Nouveaux marqueurs d'infiltrat leucocytaire de rosacee et utilisations de ceux-ci
ES2816060T3 (es) * 2012-02-29 2021-03-31 Chemocentryx Inc Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
SI2820010T1 (sl) 2012-03-01 2018-11-30 Allergan, Inc. Derivati benzofuran-2-sulfonamida kot modulatorji kemokinskih receptorjev
MX2016007128A (es) 2013-12-02 2016-08-11 Chemocentryx Inc Compuestos del receptor 6 de quimiocina (ccr6).
WO2015097122A1 (fr) 2013-12-23 2015-07-02 Norgine B.V. Benzène-sulfonamides à titre d'inhibiteurs de ccr9
US9969687B2 (en) * 2013-12-23 2018-05-15 Norgine B.V. Compounds useful as CCR9 modulators
US10000458B2 (en) * 2016-03-31 2018-06-19 Sumitomo Chemical Company, Limited Production method of 1, 2, 4-triazole compound
US12023333B2 (en) 2019-05-09 2024-07-02 Grey Wolf Therapeutics Limited Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators
WO2021007386A1 (fr) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes en tant qu'inhibiteurs de pd-l1
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
CN115477626B (zh) * 2021-06-16 2024-08-02 上海璃道医药科技有限公司 N-取代苯基磺酰胺类化合物及其用途
CN118103038A (zh) * 2021-08-20 2024-05-28 英安塔制药有限公司 17β-羟基类固醇脱氢酶13型抑制剂及其使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US6159686A (en) 1992-09-14 2000-12-12 Sri International Up-converting reporters for biological and other assays
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
DE60216606T2 (de) 2001-06-07 2007-04-05 Chemocentryx Inc., Mountain View Zellwanderungsassay
EP1507756B1 (fr) 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Inhibiteurs de ccr9 et utilisation de ceux-ci
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
DK1798223T4 (da) * 2002-11-18 2014-09-22 Chemocentryx Inc Arylsulfonamider
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
EP1643960A2 (fr) 2003-07-02 2006-04-12 Merck & Co., Inc. Derives arylsulfonamide
WO2005004818A2 (fr) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Composes heterocycliques et leur utilisation comme agents anticancereux
JP2007537275A (ja) * 2004-05-12 2007-12-20 ケモセントリックス， インコーポレイテッド アリールスルホンアミド
US9715915B2 (en) 2014-10-30 2017-07-25 Samsung Electronics Co., Ltd. Magneto-resistive devices including a free layer having different magnetic properties during operations

Also Published As

Publication number Publication date
PT2046762E (pt) 2011-05-23
JP5266219B2 (ja) 2013-08-21
EP2046762A2 (fr) 2009-04-15
ATE498615T1 (de) 2011-03-15
EA015710B1 (ru) 2011-10-31
NO341949B1 (no) 2018-02-26
UA98304C2 (uk) 2012-05-10
PL2046762T3 (pl) 2011-07-29
IL196409A (en) 2016-03-31
BRPI0714407A2 (pt) 2013-03-05
DE602007012552D1 (de) 2011-03-31
CO6180465A2 (es) 2010-07-19
KR20090053779A (ko) 2009-05-27
KR101433392B1 (ko) 2014-08-29
CA2657776A1 (fr) 2008-01-24
HK1135091A1 (en) 2010-05-28
WO2008010934A3 (fr) 2008-03-27
CA2657776C (fr) 2013-08-27
MX2009000395A (es) 2009-01-29
DK2046762T3 (da) 2011-05-09
NZ574759A (en) 2010-10-29
IL196409A0 (en) 2009-11-18
AU2007275873A1 (en) 2008-01-24
ZA200900281B (en) 2010-02-24
JP2010504908A (ja) 2010-02-18
EP2046762B1 (fr) 2011-02-16
AU2007275873B2 (en) 2012-06-14
WO2008010934A2 (fr) 2008-01-24
EA200900168A1 (ru) 2009-06-30
NO20090662L (no) 2009-03-26

Similar Documents

Publication Publication Date Title
MA30690B1 (fr) Triazolyle phenyle benzenesulfonamides
WO2008008374A3 (fr) Inhibiteurs de ccr2 et leurs procédés d'utilisation
ATE496905T1 (de) Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
MX2007008474A (es) Sulfonamidas de heteroarilo y ccr2.
WO2008008431A3 (fr) Hétéroaryle sulfonamides et ccr2/ccr9
BRPI0813695A2 (pt) Heteroaril piridil e fenila benzenossulfonamidas fundidas como moduladores de ccr2 para o tratamento de inflamação
ATE384041T1 (de) Bisarylsulfonamide
CA2865714C (fr) Sulfonamides de pyrazol-1-yl benzene convenant comme antagonistes de ccr9
DE60328690D1 (de) 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
CO6290757A2 (es) N-(2(hetarl)ari)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
EP2155203A4 (fr) Composés d'azaindazole et procédés d'utilisation
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
WO2005112916A3 (fr) Bis-aryle sulfonamides
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5